Literature DB >> 30117761

Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.

Hartmut Ruetten1, Mathias Gebauer1, Ralph H Raymond2, Roberto A Calle3, Claudio Cobelli4, Atalanta Ghosh5, R Paul Robertson6, Sudha S Shankar7, Myrlene A Staten8, Darko Stefanovski9, Adrian Vella10, Kathryn Wright11, David A Fryburg12.   

Abstract

BACKGROUND: The aims of this study were to 1. define the responses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and peptide YY (PYY) to an oral meal and to intravenous L-arginine; and 2. examine correlation of enteroendocrine hormones with insulin secretion. We hypothesized a relationship between circulating incretin concentrations and insulin secretion.
METHODS: Subjects with normal glucose tolerance (NGT, n = 23), prediabetes (PDM, n = 17), or with type 2 diabetes (T2DM, n = 22) were studied twice, following a mixed test meal (470 kCal) (mixed meal tolerance test [MMTT]) or intravenous L-arginine (arginine maximal stimulation test [AST], 5 g). GLP-1 (total and active), PYY, GIP, glucagon, and β cell function were measured before and following each stimulus.
RESULTS: Baseline enteroendocrine hormones differed across the glucose tolerance (GT) spectrum, T2DM generally >NGT and PDM. In response to MMTT, total and active GLP-1, GIP, glucagon, and PYY increased in all populations. The incremental area-under-the-curve (0-120 min) of analytes like total GLP-1 were often higher in T2DM compared with NGT and PDM (35-51%; P < 0.05). At baseline glucose, L-arginine increased total and active GLP-1 and glucagon concentrations in all GT populations (all P < 0.05). As expected, the MMTT and AST provoked differential glucose, insulin, and C-peptide responses across GT populations. Baseline or stimulated enteroendocrine hormone concentrations did not consistently correlate with either measure of β cell function. CONCLUSIONS/
INTERPRETATION: Both MMTT and AST resulted in insulin and enteroendocrine hormone responses across GT populations without consistent correlation between release of incretins and insulin, which is in line with other published research. If a defect is in the enteroendocrine/β cell axis, it is probably reduced response to rather than diminished secretion of enteroendocrine hormones.

Entities:  

Keywords:  GLP-1; arginine; incretin; insulin secretion; meal tolerance test; type 2 diabetes

Mesh:

Substances:

Year:  2018        PMID: 30117761      PMCID: PMC6167614          DOI: 10.1089/met.2018.0022

Source DB:  PubMed          Journal:  Metab Syndr Relat Disord        ISSN: 1540-4196            Impact factor:   1.894


  24 in total

1.  Influence of lysine acetyl-salicylate on glucose and arginine stimulated insulin release in man.

Authors:  T W van Haeften; T F Veneman; E A van der Veen
Journal:  Horm Metab Res       Date:  1991-04       Impact factor: 2.936

2.  Oral L-arginine stimulates GLP-1 secretion to improve glucose tolerance in male mice.

Authors:  Christoffer Clemmensen; Sanela Smajilovic; Eric P Smith; Stephen C Woods; Hans Bräuner-Osborne; Randy J Seeley; David A D'Alessio; Karen K Ryan
Journal:  Endocrinology       Date:  2013-08-19       Impact factor: 4.736

3.  Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes.

Authors:  Galina Smushkin; Airani Sathananthan; Chiara Dalla Man; Alan R Zinsmeister; Michael Camilleri; Claudio Cobelli; Robert A Rizza; Adrian Vella
Journal:  J Clin Endocrinol Metab       Date:  2011-11-16       Impact factor: 5.958

4.  The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.

Authors:  Lise L Kjems; Jens J Holst; Aage Vølund; Sten Madsbad
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

5.  Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Authors:  P V Højberg; T Vilsbøll; R Rabøl; F K Knop; M Bache; T Krarup; J J Holst; S Madsbad
Journal:  Diabetologia       Date:  2008-11-27       Impact factor: 10.122

6.  Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man.

Authors:  R Eissele; R Göke; S Willemer; H P Harthus; H Vermeer; R Arnold; B Göke
Journal:  Eur J Clin Invest       Date:  1992-04       Impact factor: 4.686

7.  Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action.

Authors:  K Faerch; A Vaag; J J Holst; C Glümer; O Pedersen; K Borch-Johnsen
Journal:  Diabetologia       Date:  2008-03-04       Impact factor: 10.122

8.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Authors:  M A Nauck; M M Heimesaat; C Orskov; J J Holst; R Ebert; W Creutzfeldt
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

9.  Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity.

Authors:  Akila De Silva; Stephen R Bloom
Journal:  Gut Liver       Date:  2012-01-12       Impact factor: 4.519

10.  Assessment of β-cell mass and α- and β-cell survival and function by arginine stimulation in human autologous islet recipients.

Authors:  R Paul Robertson; Lindsey D Bogachus; Elizabeth Oseid; Susan Parazzoli; Mary Elizabeth Patti; Michael R Rickels; Christian Schuetz; Ty Dunn; Timothy Pruett; A N Balamurugan; David E R Sutherland; Gregory Beilman; Melena D Bellin
Journal:  Diabetes       Date:  2014-09-03       Impact factor: 9.461

View more
  5 in total

1.  GLP-1 Receptor Blockade Reduces Stimulated Insulin Secretion in Fasted Subjects With Low Circulating GLP-1.

Authors:  Sarah M Gray; Andrew L Hoselton; Radha Krishna; Cris A Slentz; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2022-08-18       Impact factor: 6.134

2.  Effects of mixed meal tolerance test on gastric emptying, glucose and lipid homeostasis in obese nonhuman primates.

Authors:  Kamal Albarazanji; Andrea R Nawrocki; Bin Gao; Xiaoli Wang; Yixin Jim Wang; Yong-Fu Xiao
Journal:  Sci Rep       Date:  2021-06-04       Impact factor: 4.379

3.  Response of multiple hormones to glucose and arginine challenge in T2DM after gastric bypass.

Authors:  Giovanni Fanni; Petros Katsogiannos; Bipasha Nandi Jui; Magnus Sundbom; Susanne Hetty; Maria J Pereira; Jan W Eriksson
Journal:  Endocr Connect       Date:  2022-07-25       Impact factor: 3.221

4.  Effect of a GLP-1 mimetic on the insulin response to oral sugar testing in horses.

Authors:  Darko Stefanovski; Mary A Robinson; Andrew Van Eps
Journal:  BMC Vet Res       Date:  2022-07-29       Impact factor: 2.792

5.  Hyperglucagonemia Does Not Explain the β-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study.

Authors:  Steven E Kahn; Kieren J Mather; Silva A Arslanian; Elena Barengolts; Thomas A Buchanan; Sonia Caprio; David A Ehrmann; Tamara S Hannon; Santica Marcovina; Kristen J Nadeau; Kristina M Utzschneider; Anny H Xiang; Sharon L Edelstein
Journal:  Diabetes Care       Date:  2021-06-15       Impact factor: 17.152

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.